| ______________________________________________________________________________________________ 2005-12 All rights Reserved Biolaxy |
| IND on Oral Insulin Filed |
 | |  | |  | |  | |  | |  | |  |
| Leader in Oral Delivery of Biopharmaceuticals |
SHANGHAI, April 30, 2006 /For Immediate Release/ -- Biolaxy announced that the investigational new
drug application (IND) for oral insulin has been filed with State Food & Drug Administration (SFDA).
"It is a significant milestone achievement for Biolaxy," quoted from William Lee, CEO. "IND filing for
Nodlin is a major step forward for the company and its project development."
Nodlin is an oral insulin formulation to replace insulin injections many diabetic patients have to endure
during their life time. It is estimated that there are 30-40 million diabetic patients in China with 1.2
million new cases each year.
Biolaxy is a biopharmaceutical company focusing on oral delivery of macromolecular drugs such as
insulin and is a subsidary of NOD Pharmaceuticals. Biolaxy uses proprietary nano-particle oral delivery
or NOD technology to develop oral formulations of biopharmaceutical products.
SOURCE NOD Pharmaceuticals, Inc.
William Lee, Ph.D, CEO of NOD Pharmaceuticals, Inc., +86-21-5132-0478
URL http://www.biolaxy.com
Email info@biolaxy.com
drug application (IND) for oral insulin has been filed with State Food & Drug Administration (SFDA).
"It is a significant milestone achievement for Biolaxy," quoted from William Lee, CEO. "IND filing for
Nodlin is a major step forward for the company and its project development."
Nodlin is an oral insulin formulation to replace insulin injections many diabetic patients have to endure
during their life time. It is estimated that there are 30-40 million diabetic patients in China with 1.2
million new cases each year.
Biolaxy is a biopharmaceutical company focusing on oral delivery of macromolecular drugs such as
insulin and is a subsidary of NOD Pharmaceuticals. Biolaxy uses proprietary nano-particle oral delivery
or NOD technology to develop oral formulations of biopharmaceutical products.
SOURCE NOD Pharmaceuticals, Inc.
William Lee, Ph.D, CEO of NOD Pharmaceuticals, Inc., +86-21-5132-0478
URL http://www.biolaxy.com
Email info@biolaxy.com